Antimycobacterial Agents for Active Pulmonary Tuberculosis

Clinical Presentation and Diagnosis

A prolonged productive cough with hemoptysis is a hallmark presentation of pulmonary TB, as noted by the American Journal of Respiratory and Critical Care Medicine 1
Constitutional symptoms such as fever, night sweats, weight loss, fatigue, and malaise are common in patients with pulmonary TB, according to the American Journal of Respiratory and Critical Care Medicine 1
The combination of cough, fever, night sweats, and hemoptysis mandates immediate diagnostic evaluation and empiric treatment for TB, as recommended by Chest 4

The CDC, American Thoracic Society, and Infectious Diseases Society of America recommend a four-drug antimycobacterial regimen consisting of isoniazid, rifampin, pyrazinamide, and ethambutol for initial treatment of tuberculosis, as stated in Clinical Infectious Diseases 7
Ethambutol is critical as the fourth drug in this regimen due to unknown community isoniazid resistance rates, as noted by Clinical Infectious Diseases 7

The standard treatment course includes an intensive phase of 2 months with all four drugs, followed by a continuation phase of at least 4 months with isoniazid and rifampin, as recommended by Clinical Infectious Diseases 7
Monthly sputum smears and cultures are required until two consecutive negatives, along with baseline and monthly visual acuity/color discrimination tests due to ethambutol, as stated in Clinical Infectious Diseases 7

Respiratory isolation is mandatory until three consecutive negative sputum smears are obtained or the patient has completed 3 weeks of effective therapy with clinical improvement, as recommended by MMWR Recommendations and Reports 8
Rifampin may reduce metformin levels and interact with lisinopril, requiring close monitoring, as noted by Clinical Infectious Diseases 7
Hepatotoxicity risk is elevated in patients with chronic alcohol use, requiring close monitoring of liver enzymes throughout treatment, as stated in Clinical Infectious Diseases 7
Rapid molecular testing (Xpert MTB/RIF) and drug susceptibility testing for all first-line agents are recommended, as noted by Chest 5 and Clinical Infectious Diseases 7